Product Description
Pyrazolam (SH-I-04) is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s, and subsequently “rediscovered” and sold as a designer drug starting in 2012.
Pyrazolam has structural similarities to alprazolam[8] and bromazepam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.[3] It is most selective for the α2 and α3 subtypes of the GABAA receptor
Reviews
There are no reviews yet.